Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

BACKGROUND: The monoclonal antibody guselkumab is the first selective inhibitor of the interleukin-23 p19 subunit approved to treat adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA). Given its recent approval for active PsA, data describing patients with PsA initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., Ogdie, Alexis, Chakravarty, Soumya D., Shiff, Natalie J., Lin, Iris, McLean, Robert R., Malley, Wendi, Spitzer, Rebecca L., Kavanaugh, Arthur, Merola, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712871/
https://www.ncbi.nlm.nih.gov/pubmed/36243860
http://dx.doi.org/10.1007/s40801-022-00326-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712871/
https://www.ncbi.nlm.nih.gov/pubmed/36243860
http://dx.doi.org/10.1007/s40801-022-00326-2

Ejemplares similares